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Background: Screening with HPV is more effective than Pap test in preventing cervical
cancer. HPV as primary test will imply longer intervals and a triage test for HPV positive
women. It will also permit the development of self-sampling devices. These innovations
may affect population coverage, participation, and compliance to protocols, and likely in a
different way for less educated, poorer, and disadvantaged women.
Aim: To describe the impact on inequalities, actual or presumed, of the introduction of
HPV-based screening.
Methods:The putative HPV-based screening algorithm has been analyzed to identify critical
points for inequalities. A systematic review of the literature has been conducted search-
ing PubMed on HPV screening coverage, participation, and compliance. Results were
summarized in a narrative synthesis.
Results: Knowledge about HPV and cervical cancer was lower in women with low socio-
economic status and in disadvantaged groups. A correct communication can reduce dif-
ferences. Longer intervals will make it easier to achieve high-population coverage, but
higher cost of the test in private providers could reduce the use of opportunistic screening
by disadvantaged women. There are some evidences that inviting for HPV test instead
of Pap increases participation, but there are no data on social differences. Self-sampling
devices are effective in increasing participation and coverage. Some studies showed that
the acceptability of self-sampling is higher in more educated women, but there is also an
effect on hard-to-reach women. Communication of HPV positivity may increase anxiety
and impact on sexual behaviors, the effect is stronger in low educated and disadvantaged
women. Finally, many studies found indirect evidence that unvaccinated women are or will
be more probably under-screened.
Conclusion: The introduction of HPV test may increase population coverage, but non-
compliance to protocols and interaction with opportunistic screening can increase the
existing inequalities.
Keywords: human papillomavirus, mass screening, social inequalities, participation, coverage, compliance
BACKGROUND
Cervical cancer is still the fourth cancer worldwide in terms of
incidence, although the burden of disease is not evenly distrib-
uted, with about 80% of cases occurring in low-income countries
(1). In industrialized countries, instead, incidence and mortality
have been dramatically reduced thanks to Pap test and screening
programs (2, 3). In fact, the Pap test is able to identify cytological
abnormalities exfoliated from pre-cancerous lesions, and progres-
sion to cervical cancer is prevented through outpatient treatment
(2, 3).
Persistent infection with HPV oncogenic types has been
demonstrated to be the necessary, but not sufficient, cause of cer-
vical cancer (3). Knowledge of the natural history of the disease
has led to the introduction of two new tools for cervical cancer
prevention: vaccine and HPV test for screening (4).
Population-based randomized trials have shown that screen-
ing with HPV as primary test is more effective than Pap test in
reducing cervical cancer incidence (5) and mortality (6).
The accuracy characteristics of the HPV DNA test are different
from those of the Pap test. First and foremost, the former is more
sensitive and less specific (7). Further, it has a higher prospec-
tive negative predictive value, i.e., the risk of having a CIN3 or
cancer 5 years after an HPV-negative test is still lower than the
risk 3 years after a negative Pap test (5, 8). Due to lower speci-
ficity a higher number of women will need further ascertainment.
However, few of them will have a high-grade lesion and direct
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referral to colposcopy may thus be too intensive an approach (9–
11). On the other hand, higher sensitivity and prospective negative
predictive value will allow longer intervals (5, 8). HPV infection
can persist for several years before its clearance or progression
to a high-grade lesion requiring treatment; women with long-
term persistent infections need to be followed up with reasonable
protocols, adapted to their risk of developing cancer (12).
Therefore the shift from Pap test to HPV test as a primary
screening test will dramatically change the screening program pro-
tocols and organization: the intervals will be longer, and a triage
test for HPV positive women and more complex algorithms for
the management of positive women will be needed. Furthermore,
the introduction of HPV test will result in less intensive protocols
and follow up. Finally, a molecular test makes it possible to develop
self-sampling devices.
All these changes and technical innovations may affect screen-
ing participation and population coverage (11, 13), and most
likely in a different way for less educated, poorer, and more
disadvantaged women (14–16).
To date, only few countries have introduced the HPV test in
the organized screening protocol and none has yet implemented
such protocols at a national level; several countries have large-scale
population-based pilot projects under way (17–21).
OBJECTIVE
To identify the possible effect of the introduction of HPV-based
protocols in organized screening program on social inequalities
by means of an analysis of the process and of a systematic review
of the literature. The analysis is focused on countries with public
organized screening programs.
METHODS
DEFINITION OF THE PUTATIVE ALGORITHM FOR HPV-BASED
SCREENING
After an initial search of the meta-literature (systematic reviews,
HTA reports, guidelines, and narrative reviews) on implementing
an HPV-based screening and social inequalities in cervical can-
cer prevention, we analyzed the putative screening algorithm with
HPV as primary screening, as included in the up-coming European
guidelines (9), to identify all the critical points where inequalities
in coverage, participation, and compliance to protocols, and in the
effectiveness of screening program could be generated or reduced.
SCOPE
To define the scope of the systematic review we analyzed the flow-
chart of the algorithm to identify those points where new inequali-
ties might be introduced and/or where existing inequalities might
be reduced. Relevant topics should have two characteristics: (1)
there should be a noticeable change with the introduction of the
HPV-based screening; (2) the topic should be potentially related
to socioeconomic inequalities. Among the parameters measuring
the effectiveness of an organized screening program, test coverage,
participation, and compliance have a “per se” effect on equity (9).
SYSTEMATIC REVIEW
Literature search
A systematic review of the literature was conducted on PubMed
and the European public screening program websites to identify
relevant publications on HPV screening and coverage, participa-
tion, and compliance.
The PubMed search strategy was defined according to the meth-
ods used in two previous systematic reviews, one on the methods to
increase participation in screening (9, 22, 23) the other on inequal-
ities and screening (24). To the original search of the systematic
review on methods to increase participation we added terms to
identify those focusing on inequalities as well as terms to specify
HPV-based screening (HPV or human papillomavirus). The ref-
erences of all the relevant papers were checked to identify other
potentially relevant papers.
The search was limited to the period from 1/1/2000 to
31/7/2013. The rationale for limiting the search to 2000 is
that in the 1990s there were no population-based experiences
of HPV screening. Furthermore, the screening algorithms now
proposed in organized screening were defined in the early
2000s (25).
Inclusion criteria
From the studies retrieved, we first selected those that were poten-
tially relevant by reading the abstract. The abstract should present
data or hypothesis on association or interaction between HPV
knowledge, HPV screening attendance, and/or attitude and social,
cultural, economic, and/or ethnic inequalities.
Due to resource limitations, the title and abstract screen-
ing was carried out by only one researcher (Flavia Baldacchini)
and subsequently checked by a second author (Paolo Giorgi
Rossi) by crosschecking the references. The full text of the rel-
evant studies were then analyzed to identify and classify the
information or hypothesis reported. A further number of stud-
ies was excluded in this step because the discussion of HPV
and inequalities was too vague or because the paper focused
exclusively on vaccination campaigns. The inclusion criteria were
evaluated by two authors independently (Flavia Baldacchini and
Paolo Giorgi Rossi); discordant cases were discussed to reach an
agreement.
We did not perform any quality analysis since we were inter-
ested in identifying any issues that may be relevant, which could
emerge even in low-quality papers.
Data extraction and narrative synthesis
From each paper the following data were extracted: publica-
tion year, author, title, topic(s) analyzed, outcome considered,
study design, population, synthesis of results, and synthesis of the
authors’ conclusions.
Information from the selected papers was extracted according
to its relevance with the topics listed in the flowchart analysis.
Topics that emerged from the literature search and not postu-
lated in the flowchart analysis were also identified and reported
in the results. The papers were also classified according to the
outcome considered: knowledge, test coverage, screening attitude
and/or screening participation, compliance to protocols, and anx-
iety. In addition, we considered papers concerning the interactions
between vaccine and screening.
Systematic review results are summarized in a narrative syn-
thesis.
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RESULTS
FLOWCHART ANALYSIS AND SEARCH RESULTS
The critical points reported in Figure 1 were identified in the
preliminary analysis of the meta-literature. They can be grouped
into four main topics: test coverage of the population, participa-
tion in screening program, compliance to the screening protocols
and referral strategies, and communication of positive results and
related anxiety. Of the papers treating the effects on test cover-
age and screening participation, a relevant number focused on the
possible use of self-sampling. Furthermore, two topics not directly
linked to the screening protocol were identified: knowledge and
communication strategies of HPV and the interaction between
screening and HPV vaccine.
One hundred and forty-nine abstracts were initially identified.
Of these, 121 were considered relevant, with 86 included after
full text examination (Figure 2). During the literature analysis we
summarized the information reported by each study according to
the general issue for which it was relevant (Figure 1).
KNOWLEDGE AND COMMUNICATION STRATEGIES
The systematic review identified 23 studies on knowledge about
HPV that reported differences in socio-economic status lev-
els or interaction between SES and effectiveness of informa-
tion/communication tools or strategies.
In general, the more deprived women, with lower educa-
tional level or SES, and women in more disadvantaged ethnic
groups knew less about HPV and cervical cancer risk. Vanslyke
and colleagues (26) found that knowledge of HPV was generally
very limited among Hispanic women aged 18–60. Furthermore,
an indirect evidence of inequality among Hispanics came from
the comparison of the Health Interview National Trends Survey
(HINTS) and a cross-section of callers to the National Cancer
Institute’s (NCI) cancer information service (CIS) (27). Luque
and colleagues (42) observed greater awareness of HPV and the
HPV vaccine among Anglo American and Puerto Rican women
than among Mexican and Honduran women. Al-Naggar and col-
leagues (28) examined the level of knowledge and barriers against
FIGURE 1 | Putative screening algorithm according to the up-coming
European guidelines (9) and critical points related to social inequalities.
Along the pathways depicted by the screening algorithm flowchart, the
callouts explain where critical points for increasing or decreasing social
inequalities have been identified or hypothesized. The color code of the
callouts corresponds to the main topics, as reported inTable 1 and Figure 2,
to which the critical point refers: in blue, points related to test coverage of the
target population; in yellow, points related to participation in screening
programs; in green, points related to compliance with screening protocols; in
orange, points related with communication of positive results and anxiety.
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FIGURE 2 | Flowchart of the systematic search. The color code of the main topics is the same as reported in Figure 1.
cervical cancer screening of female university students in Selan-
gor, Malaysia and found that age, marital status, ethnicity, and
monthly family income, were significantly associated with knowl-
edge of cervical cancer screening. Vogtmann and colleagues (29)
evaluated the demographic and behavioral factors associated with
HPV awareness and knowledge in a population of Mexican col-
lege students and found that characteristics associated with not
having heard about HPV were being male, not having running
water, not having health insurance, and not having sexual experi-
ence. In the UK, Waller and colleagues (30) found that women and
more educated people had better knowledge of the established risk
factors for cervical cancer and HPV and in Germany, Klug and col-
leagues (33) found an association with social class. Only one study
on Turkish sexual workers found almost no association between
HPV knowledge and educational level (34).
Most of the studies were conducted before the introduction
of HPV vaccine. Indeed, it is very likely that the knowledge and
awareness of HPV strongly increased in the years around the intro-
duction of mass vaccination campaigns in 2007–2009. This was
confirmed by some focus groups conducted with women partic-
ipating in the Florence, Italy cervical cancer screening in 2007
and 2011 (35, 36). It is also likely that the increase in knowl-
edge was more relevant for less educated women who started
out with a lower level of knowledge. Nevertheless, the PREGIO
study, conducted in Italy during the launch of the mass vaccina-
tion of 12-year-old girls in 2008, found that knowledge of Pap test
was still greater than the knowledge of HPV and cervical cancer,
although more than 70% correctly answered questions on virus
transmission and the role of HPV in cancerogenicity (37). Women
with higher educational level had greater knowledge about HPV
and cervical cancer prevention but had similar attitudes toward
undergoing vaccination. Two recent studies conducted in France
(38) and Germany (39), instead, found there was still very lit-
tle knowledge (16%) of the link between HPV and cervical cancer
and an insufficient HPV awareness and low vaccination prevalence
among young women.
Three trials and one case–control study compared different
strategies to provide information on HPV. Lloyd and colleagues
(43) observed an increase in knowledge in 13–16-year-old girls
with an increase in fear but not in anxiety about infections after
the distribution of a leaflet (not specific for HPV test and includ-
ing other sexually transmitted diseases as well). Similar results
were observed by Papa and colleagues (44) in women undergoing
an HPV test and by Marek and colleagues (45) after a brief HPV-
oriented program for adolescent. A limit of these two studies was
the absence of information about SES. Wetzel and colleagues (46)
evaluated the efficacy of a short counseling program and observed
an increase in knowledge. The intervention was effective in reduc-
ing the existing differences between black and white women and
between those with Medicaid and those with private insurance.
Other authors have tried to provide insights into effective com-
munication about HPV, but with little supporting evidence (47,
48) and no mention of how to reduce SES inequalities.
COVERAGE OF THE TARGET POPULATION
Longer intervals will influence the test population coverage
because the definition of test coverage will change, but also because
there may be an impact on women’s behaviors and attitude. There
are no direct evidences, experimental or observational, in the
literature on this point.
Most of the literature is only speculative. Our systematic review
retrieved eight studies on coverage and HPV-based screening that
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Table 1 | Summary of the questions and results emerged from the systematic review.
Topic Reference Question Summary of the results
Knowledge (26–42) Differences in knowledge Almost all studies found a gradient in knowledge about HPV and
cervical cancer with any of the variables used to measure SES or
deprivation: educational level, disadvantaged groups, etc
(43–48) Effective tools to improve knowledge and
reduce inequalities
Differences tend to diminish after any kind intervention to inform
women. Results about written material are inconclusive; short
counseling showed to be effective
Coverage (16, 49–51) Longer screening intervals can increase the
coverage for hard-to-reach population
No data are available
(9, 52) Access to opportunistic HPV testing could be
limited by the high cost of the test in private
laboratories
No data are available
(49, 53, 54) Self-sampling device could be used to reduce
sampling costs, but could affect coverage
Only one trial conducted in Mexico. A lower coverage was
achieved, but it was due to women not found at home and to
whom the self-sampling was not mailed
Participation (9, 13, 16, 17, 21,
26, 32, 50, 52, 53,
55–57)
The proposal of a new test may change the
participation
Several observational studies and one trial found a small increase
in participation when invited for a HPV test compared to Pap test.
No data on how it will impact on inequalities
Longer intervals could disrupt the habits,
thereby of women reducing participation
No data are available
(14, 22, 49,
53–55, 58–75)
Self-sampling device could be used to
participation in screening program
Nine studies showed a positive effect of self-sampling in
under-screened population. Some studies showed that the device
is acceptable also among disadvantage women, even in some
case to a minor extent
Compliance
to screening
protocols
(41) Longer intervals could increase opportunistic
over-screening
No data are available
(9, 21, 35, 36, 57) Referral to early rescreen after HPV positive
cytology-negative test could increase use of
unnecessary ascertainment
No data are available
(17, 21, 76, 77) Referral to early rescreen after HPV positive
cytology-negative test could result in
substantial loss to follow up
The compliance to early rescreen in this group of women varied
among studies, showing that correct communication can reduce
loss to follow up. No data about differences in socio-economic
status are available
Communication
of positive
results
(2, 9, 78–81) Communication of HPV positivity can induce
anxiety
Several studies showed anxiety after the communication of Pap
test and/or HPV positivity. Women with higher educational level
are advantaged in understanding the gynecologist’s and midwife’s
recommendations and explanations
(32, 40, 79, 80,
82–84)
Communication of HPV positivity can induce
changes in sexual habits
Some studies showed concern about the sexual transmission of
the virus. These concerns were stronger in women of lower
educational level and disadvantaged ethnic groups
(31, 36, 84–91) Effective ways to reduce anxiety and other
adverse effects
Face-to-face counseling was preferred by women, but cannot be
used only for positive results because of the anxiety caused by
the understanding that the test was positive and the need to wait
for the counseling. Short phone counseling only for positive was
also appreciated
Interaction
vaccine and
screening
(38, 92–98) Negative effect of vaccine on future screening Only one studies reported a small proportion of girls referring that
vaccination would change their attitude to screening
(56, 99–103) Association between vaccine and screening
attitudes
Several studies showed an association between vaccine and
screening attitude or between vaccination and screening coverage
in mothers. Results are heterogeneous
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treated social inequalities. Some authors speculated on the effect
of longer intervals, and the two options are reported (16, 49–51):
longer intervals can facilitate achieving high-population cover-
age; longer intervals may disrupt women’s habits and thus have
detrimental effects on coverage. The second hypothesis is usually
supposed to affect especially deprived women (16).
Many countries have a mixed model with opportunistic and
organized screening existing together and sometimes competing
for participation (104, 105). Only two documents mention the
consequences on social inequalities of the interaction between
spontaneous and organized screening in the era of HPV-based
screening (9, 52). The introduction of HPV as primary screening
test may have some consequences in this context and can surely
change the inequality scenario: in the opportunistic setting, HPV
will be much more expensive than Pap test, at least in the short
term. If opportunistic screening offers the two options, less wealthy
women will be pushed to undergo Pap test and richer ones HPV,
regardless of what would be more appropriate. If the diffusion
of HPV testing in the opportunistic setting were stronger and
the offer of Pap almost disappeared, the coverage in less wealthy
women would decrease or these women would be induced to
participate in organized screening programs. Finally, if the screen-
ing programs are reinforced by the introduction of HPV testing,
it is likely that inequalities will decrease, as already observed in
countries with well-established organized screening programs for
cervical and breast cancer (106).
PARTICIPATION IN SCREENING PROGRAM
The proposal of a new test may influence attendance. Thirty-five
studies were found, but only one trial (53) and three intervention
studies with historical controls (17, 21, 50) compared the par-
ticipation in HPV-based vs. cytology-based screening program.
The only trial (53) focused on self-sampling, but used as control
groups both standard invitation to have a Pap test at the clinic and
an invitation to have an HPV test at the clinic. The sample size
was small and the population was selected to be non-responder to
the first invitation, but it found an 8%, non-significant increase
in participation. Data from pilot studies showed in most cases
a higher participation in HPV-based screening than in Pap test-
based screening. In particular, two Italian studies showed a 10%
increase in coverage (17, 21). The increase was stronger in younger
women, a group less covered than older women in Italy (17).
Another study (50) found that after the initial diffidence, His-
panic and black women were more likely to undergo HPV test
than were white women. Some other papers reported the results
of pilot or demonstration studies but without any term of com-
parison. Levinson and colleagues (55) found high acceptability in
underserved Peruvian women, Marlow and colleagues (56) found
that, in contrast to screening attendance, ethnicity plays an impor-
tant role in HPV testing, and finally, Philips and colleagues (13)
report that adding HPV-based triage to the Pap program lowered
the value of screening participation for only two women, whereas
for the sample as a whole, it increased the average valuation by
about 47%.
It is difficult to predict what impact the increase in participation
will have on test coverage, but the increased costs in opportunis-
tic screening and the increased appeal of programs offering the
HPV test will probably increase participation in organized screen-
ing. Part of this increase will probably involve some women who
are under- or never-screened, which will result in a substantial
reduction in inequality of access and in the burden of disease (107).
USE OF SELF-SAMPLING DEVICES
Self-sampling devices can be used to increase coverage and/or par-
ticipation among non-responders. Twenty-four studies treated the
effect of self-sampling on coverage or participation. Nine trials
(53, 54, 58, 60–65) and four reviews (22, 66–68) found a positive
effect of direct home mailing of the device, while other ways of
offering the device are not effective (53). Among studies reporting
the acceptability of self-sampling among women, one showed that
it was higher among married women and less accepted by some
ethnic groups, such as Asians in the UK (69) and another found
(73) that it was higher among those with some or more college
education (43 vs. 26%), and among those who were not Hispanic
compared to Hispanic (49 vs. 28%). However, four studies found
high acceptability also in the most hard-to-reach women (67, 70,
71, 74). One of the main concerns in women performing self-
sampling is not collecting an adequate sample (53, 69, 72, 75). This
concern is stronger among Indian and African Caribbean women
than among white British women (75). In particular, two trials
in France conducted in two neighborhoods with different socio-
economic levels (62, 64) measured the difference in effectiveness
of self-sampling in increasing coverage: they observed that the rel-
ative risk of having a test was higher in low socio-economic status
women but that the impact was limited in both contexts due to low
participation and very low compliance to colposcopies in positive
women. A study in the Netherlands (59), found that self-sampling
was effective in increasing coverage among under-covered popula-
tions, but the response rate was higher in native-Dutch women and
in women who already had a previous Pap test. Another study, con-
ducted in central Italy, found no effect of self-sampling in a rural
area and a relevant effect in urban areas (53), while a Swedish study
found no difference in acceptance in different SES levels (108).
These studies, designed to test self-sampling as a tool to improve
Pap test-based programs, suggest that the most deprived women,
even in HPV-based programs, will have more difficulty accepting
self-sampling, but an increase in compliance can be obtained in
most of the socio-economic groups.
Self-sampling devices can also be used to reduce sampling costs,
though it could influence participation. Only one large trial in
Mexico (49) tested self-sampling as first approach method and
showed a lower participation for self-sampling than for Pap test
when all the population was included in the analyses. If, however,
we exclude women not found at home and to whom the self-
sampling device was not mailed, the participation was over 98%.
Such a result has the potential to eliminate any inequality in access
to screening, providing we have complete lists of resident women
with updated and accurate addresses.
COMPLIANCE TO SCREENING PROTOCOLS
Nine papers treated the differences in compliance with respect to
HPV-related protocols.
Compliance to a 5-year interval after HPV-negative test may
be low for women used to having a Pap test every year (41),
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thereby increasing spontaneous opportunistic over-screening. No
published data were found about compliance to the recommended
interval after HPV. Previous studies found an association between
intervals shorter than recommended and high socio-economic sta-
tus women (109, 110). Consequently, if over-screening increases,
the phenomenon will probably be less relevant for deprived
women.
Non-compliance with the recommendation to repeat test after
1 year (or 6 months), both in terms of under- and over-screening,
may be influenced by socio-economic status. It has been observed
that women have an overwhelming preference for immediate col-
poscopy rather than continued surveillance for persistent HPV
(57). Cultural background can influence the compliance to proto-
col and increase or decrease the induced anxiety when a woman
receives a result of HPV positivity and there is no immediate
referral to further assessment.
Some authors considered the implication of effective commu-
nication of the test results on compliance to 1-year follow up (9,
21). The implications differ depending on whether it is necessary
to invite the women back to collect a cytologic sample or whether
the sampling method allows reflex cytology in to be performed
(a liquid-based cytology or a double sampling taken at the same
moment). In the first case, high compliance is needed to obtain the
second sample. If the Pap test is negative, women who are HPV
positive and Pap test negative must be reassured about waiting
1 year before repeating the test so as to avoid unnecessary colpo-
scopies or other evaluations during that period. In the case of a
reflex cytology test, we can give the HPV and cytology results at
the same time, leaving only the problem of reassuring women for
the 1-year follow up. Compliance to protocols varied dramatically
among trials and pilot studies results, with some programs obtain-
ing more than 85% without any particular interventions (17) and
other pilot studies (21) and trials with relevant loss to follow up
in HPV positive women (76, 77) when colposcopy was delayed.
In some cases there was an evidence of over-screening (21), but
there are no data on SES differences. In a non-randomized study, a
brief phone counseling at the moment of HPV positivity strongly
increased the compliance (65 vs. 35%) to 1-year follow up (21).
All the problems related to compliance to recommended pro-
tocols are more critical when a strong opportunistic offer is
present (52, 111), in particular when there is a risk of overuse
of screening test (i.e., shorter intervals or extra Pap test in HPV-
negative women) and of evaluations (i.e., extra colposcopies in
HPV positive cytology-negative women). In fact, in opportunis-
tic screening gynecologists usually recommend a yearly Pap test
and women are used to shorter intervals than that recommended
by organized screening. In some focus groups (35, 36), a cer-
tain diffidence against longer intervals emerged when proposed
by the public health system because it was perceived as a bud-
get cut rather than a measure to avoid overtreatment (112). Even
if this sort of skepticism may be present in all cultural and eco-
nomic strata of society, the effect on compliance will probably be
greater among women with higher SES because they undergo reg-
ular gynecological exams more frequently than do women with
low SES.
The only way to reduce negative interactions between orga-
nized and opportunistic screening during the HPV screening
implementation is to reduce discrepancies between organized
program protocols and the attitudes/recommendations of gyne-
cologists and general practitioners working outside the program,
be they public or private providers. How to achieve this is beyond
of the scope of this paper, but education and participation in the
definition of local protocols, within the limits imposed by the
evidence, are necessary steps in the process (113, 114).
COMMUNICATION OF POSITIVE RESULTS AND RELATED ANXIETY
Finally, the communication of HPV infection positivity poses new
problems combining the anxiety and the implications related to a
sexually transmitted disease with that related to cancer (79, 80). We
found 20 papers on the communication of positive results and how
a woman’s socio-economic status can affect how she receives it.
Previous systematic review (2, 9, 78) found that communicat-
ing the result of an abnormal Pap smear may induce anxiety, fear
of malignancy, difficulties in sexual intercourse, a different per-
ception of the body, and fear of becoming infertile (115–118).
Furthermore, some women reported fear of pain caused by col-
poscopy and treatment, which may cause loss to follow up (117).
One paper shows that the anxiety induced by positive Pap test
results (81) was stronger in women with low socio-economic sta-
tus. Indeed, we can suppose that many of the feelings related to
a positive result are determined by the woman’s knowledge and
ability to understand the midwife’s or gynecologist’s indications,
which is almost certainly associated with her educational level.
All these concerns are also valid in HPV-based screening and
may be even more intense given the higher proportion of posi-
tive women (82). Furthermore, there are concerns that are unique
to HPV-based screening: since this test explicitly targets a sexually
transmitted virus, positivity may have an impact on sexual behav-
iors and relationships (40, 82). This concern has been shown to be
higher in low education level women and non-white ethnic groups
in the UK (32), and more in general, to women’s social status (mar-
ried vs. unmarried), sexual history (number of partners), cultural
background (sexual norms and practices), and knowledge and
understanding of the link between HPV and cancer (83). Several
studies dealing with this found that current and past relationships,
cultural norms concerning sexual habits, and knowledge of HPV
and cervical cancer were possible modifiers of the psychological
response to a positive result (82). Two studies using focus groups
to evaluate the health education material and response letters of a
pilot screening program found that the women asked for shorter
texts and simpler wording; the greatest concerns were related to
the difficulty in understanding the real risk of cancer (36, 87).
Finally, Waller et al. (31) concluded that the way in which infor-
mation is presented to women may be crucial in minimizing the
negative psychological impact of testing positive and ensuring that
participation in screening remains high.
Eight studies analyzed the health information needs of women
undergoing an HPV test and in particular, of those receiving a
result of positivity (84–91). Only one, based on Pap test expe-
rience, reports the results of different communication strategies.
However, given the low number of participants (20 women), the
authors could not determine whether effectiveness was associated
with SES. Women questioned whether communicating results by
letter would violate their privacy and generally preferred receiving
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a phone call because it permits immediate clarification, thereby
reducing anxiety. The most preferred mode was face-to-face com-
munication, for negative and positive results alike. In fact, they
were worried that a differentiated mode of communication (let-
ter for negative results and face-to-face for positive results) would
increase their anxiety because the amount of time that elapsed
from the date of the appointment would implicitly mean a positive
result, to be confirmed or not during the counseling itself (84).
Obviously, a phone call and face-to-face communication make
it possible to modulate the message according to the woman’s
coping, linguistic abilities, and educational level. However, there
are two main obstacles to implementing face-to-face communica-
tion: it is very time-consuming and, to avoid increasing anxiety, it
should be done for both negative and positive results.
VACCINE AND SCREENING INTERACTION
One of the most treated topics in the literature was the interac-
tion between vaccination and screening, with 14 papers directly
reporting data on this topic. Two main points were treated: (1) the
effect of vaccination on women’s attitude to screening and con-
sequently on test coverage (92–94, 96–98), the hypothesis is that
being vaccinated could change future participation in screening
[usually the authors suggest a decrease – Ref. (93, 94)]; (2) the
association between vaccination and future screening attitude (56,
99–102), i.e., those girls who do not do the vaccination now are
probably those who will not participate in screening in the future.
The consequence is that the impact on cervical cancer screening
of vaccinated cohorts will be minimal because most cancers will
occur in women not vaccinated and not screened (95). These two
phenomena are not typical of the HPV-based screening and most
of the literature considered the relation between vaccination and
Pap test use.
The first point has been treated by Brotherton and colleagues,
with interviews to girls to whom vaccination had been proposed:
only 8% said that HPV vaccine could have a negative effect on
their future screening habits.
As for the second point, two study designs have been used:
attitude interviews to vaccinated and unvaccinated girls already
in or close to the screening target age (99, 103); for younger
girls, the association between the mother’s Pap test use and the
daughter’s vaccination state (56, 100, 101). The results are mixed:
two studies (56, 99) found no association while the others found
a strong association between vaccination and screening (99) or
between mother’s participation in screening and her daughter’s
being vaccinated (100–102).
None of the studies hypothesized how the introduction of HPV
test might modify these phenomena. Only the study by Marlow
and colleagues explicitly measured attitudes to HPV testing.
The general opinion is that HPV should be the primary screen-
ing test in vaccinated cohorts (119) and research on vaccine
and screening interaction should be directed to define the best
screening algorithms for vaccinated women.
CONCLUSION
Since equity in access is one of the main objectives of organized
screening programs, the introduction of HPV test may be a way to
increase population coverage and thus finally include some of the
hard-to-reach women. Interactions with spontaneous screening
may increase over-screening and inappropriate use of evaluation
tests although this phenomenon is likely to be more relevant
among women with higher socio-economic status.
There remain, however, problems concerning how to commu-
nicate positive results, control induced anxiety, and reduce non-
compliance to protocols, which may augment existing inequalities
if particular attention is not paid to effective communication.
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